D.E. Shaw & Co
TTNP

D.E. Shaw & Co’s Titan Pharmaceuticals TTNP Stock Holding History

D.E. Shaw & Co’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10
Closed -$63K – 3741
2017
Q3 		$63K Sell
10
-2
-17% -$12.4K ﹤0.01% 3393
2017
Q2 		$84K Buy
12
+5
+71% +$46.5K ﹤0.01% 3277
2017
Q1 		$84K Hold
7
– – ﹤0.01% 3201
2016
Q4 		$106K Hold
7
– – ﹤0.01% 3341
2016
Q3 		$150K Buy
+7
New +$136K ﹤0.01% 3241

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SRAM
Stone Ridge Asset Management New York $475M AUM
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

D.E. Shaw & Co's TTNP Position: Q4 2017 in Review

D.E. Shaw & Co sold out of Titan Pharmaceuticals (TTNP) in Q4 2017, closing a stake of 10 shares — an estimated $63K sold.

D.E. Shaw & Co first reported a position in TTNP in Q3 2016 and held it in 5 quarters. The position peaked at $150K in Q3 2016. 21 funds tracked by Wall St. Rank hold TTNP as of Q4 2017.

  • D.E. Shaw & Co reported no remaining Titan Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 10 Titan Pharmaceuticals shares in Q4 2017, an estimated $63K.
  • D.E. Shaw & Co first reported a position in Titan Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • D.E. Shaw & Co's Titan Pharmaceuticals position peaked at $150K in Q3 2016.
  • 21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2017.

Based on D.E. Shaw & Co's 13F filing for Q4 2017, filed 14 Feb 2018.